

Christopher P Cannon

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/9381891/publications.pdf](https://exaly.com/author-pdf/9381891/publications.pdf)

Version: 2024-02-01

492
papers

86,156
citations

727

117
h-index

319

283
g-index

558
all docs

558
docs citations

558
times ranked

43140
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial. <i>Circulation</i> , 2024, 149, 1802-1811.	6.2	0
2	Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry. <i>Journal of the American Heart Association</i> , 2024, 13, .	3.8	1
3	Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the <sc>VERTIS CV</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 3478-3481.	4.5	0
4	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. <i>Sleep and Breathing</i> , 2023, 27, 669-672.	1.9	12
5	A polygenic risk score predicts atrial fibrillation in cardiovascular disease. <i>European Heart Journal</i> , 2023, 44, 221-231.	2.2	28
6	Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. <i>European Heart Journal</i> , 2023, 44, 293-300.	2.2	37
7	Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from <sc>VERTIS CV</sc>, a randomized trial of the <sc>sodium-glucose cotransporterâ€2</sc> inhibitor ertugliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 758-766.	4.5	6
8	Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the <sc>VERTIS CV</sc> population with type 2 diabetes and atherosclerotic cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1398-1402.	4.5	1
9	Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2042-2051.	3.5	2
10	Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1750-1757.	4.5	5
11	Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVIDâ€19 Pandemic. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.8	14
12	Impact of Ezetimibe on Newâ€Onset Diabetes: A Substudy of IMPROVEâ€T. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.8	4
13	Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. <i>European Heart Journal</i> , 2023, 44, 5163-5166.	2.2	2
14	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	3.0	24
15	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. <i>American Heart Journal</i> , 2022, 243, 15-27.	3.0	8
16	LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. <i>Journal of Lipid Research</i> , 2022, 63, 100148.	4.1	28
17	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	4.3	9
18	Cardiovascular Events and Longâ€Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€T. <i>Journal of the American Heart Association</i> , 2022, 11, e022733.	3.8	5

#	ARTICLE	IF	CITATIONS
19	Statin intolerance: how common is it and how do we work with patients to overcome it?. European Heart Journal, 2022, 43, 3224-3226.	2.2	9
20	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083.	4.5	26
21	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1114-1122.	4.5	5
22	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1245-1254.	4.5	7
23	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia, 2022, 65, 908-911.	6.4	1
24	Impact of coronary artery calcium testing on patient management. Journal of Cardiovascular Computed Tomography, 2022, 16, 303-308.	1.3	6
25	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention, 2022, 18, e292-e302.	3.3	5
26	Association of Influenza Vaccination With Cardiovascular Risk. JAMA Network Open, 2022, 5, e228873.	5.9	76
27	Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. Kidney International Reports, 2022, 7, 1782-1792.	0.8	4
28	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	4.5	15
29	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2022, 24, 1829-1839.	4.5	27
30	Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?. European Heart Journal Open, 2022, 2, .	2.3	5
31	A remote hypertension management program clinical algorithm. Clinical Cardiology, 2022, 45, 1147-1162.	1.9	6
32	Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-of-Pocket Expenses? Insights From ARTEMIS. Journal of the American Heart Association, 2022, 11, .	3.8	0
33	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. European Journal of Preventive Cardiology, 2021, 28, e12-e14.	1.8	10
34	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 148.	6.3	718
35	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	29.6	1,212
36	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	29.6	749

#	ARTICLE	IF	CITATIONS
37	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. <i>Circulation</i> , 2021, 143, 602-605.	6.2	26
38	Digital Care Transformation. <i>Circulation</i> , 2021, 143, 507-509.	6.2	42
39	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. <i>JAMA Cardiology</i> , 2021, 6, 582.	6.3	5
40	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 629-658.	5.5	175
41	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	6.2	36
42	Insights from CRENDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	5.3	109
43	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	3.0	25
44	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 153-163.	1.0	13
45	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	6.9	74
46	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.	3.0	17
47	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	6.2	23
48	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	4.3	41
49	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	6.2	140
50	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	3.0	7
51	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , 2021, 64, 1256-1267.	6.4	114
52	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CRENDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	3.0	36
53	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <sc>CRENDENCE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	4.5	9
54	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2021, 110, 1612-1624.	3.4	14

#	ARTICLE	IF	CITATIONS
55	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC: Cardiovascular Interventions, 2021, 14, 768-780.	3.5	6
56	Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation. American Journal of Cardiology, 2021, 144, S32-S39.	1.5	2
57	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	6.2	68
58	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL) Tj ETQq0 0 0 ggBT /Overlock 10 T Cardiology, 2021, 44, 1002-1010.	1.9	2
59	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	5.0	70
60	Kidney outcomes using a sustained $\geq 40\%$ decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clinical Cardiology, 2021, 44, 1139-1143.	1.9	22
61	Ertugliflozin and Slope of Chronic eGFR. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1345-1354.	4.3	30
62	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 77, 3016-3027.	5.5	26
63	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	2.2	90
64	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	10.0	40
65	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiology, 2021, 6, 1440.	6.3	55
66	Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention, 2021, 17, 474-480.	3.3	5
67	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. Journal of the American Heart Association, 2021, 10, e020893.	3.8	9
68	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. JAMA Cardiology, 2021, 6, 880.	6.3	41
69	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiology, 2021, 6, 1060.	6.3	105
70	An Update on Aspirin for Cardioprevention: Implications for Patient Care. , 2021, 70, S1-S10.		0
71	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 78, 1499-1507.	5.5	27
72	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e29-e30.	3.0	1

#	ARTICLE	IF	CITATIONS
73	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c $\leq 7\%$. <i>Circulation</i> , 2020, 141, 407-410.	6.2	101
74	Association of a P2Y ₁₂ Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. <i>JAMA Cardiology</i> , 2020, 5, 38.	6.3	6
75	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , 2020, 219, 70-77.	3.0	18
76	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 238-240.	5.5	3
77	Atrial Failure as a Clinical Entity. <i>Journal of the American College of Cardiology</i> , 2020, 75, 222-232.	5.5	197
78	Lp(a)'s Odyssey. <i>Journal of the American College of Cardiology</i> , 2020, 75, 145-147.	5.5	3
79	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e012797.	3.8	29
80	Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older"Reply. <i>JAMA Cardiology</i> , 2020, 5, 235.	6.3	0
81	Comparison of the Effect of Age (≤ 75 Versus > 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or) $\frac{1.5}{14} \times 10.7843$	1.5	14
82	Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 707-719.	1.5	6
83	Novel Oral Anticoagulants Following Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008465.	4.1	7
84	Effects of Canagliflozin in Patients with Baseline eGFR ≤ 30 ml/min per 1.73 m ² . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	4.3	97
85	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1012-1014.	3.5	6
86	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e016506.	3.8	8
87	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 1425-1435.	29.6	1,014
88	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. <i>Clinical Cardiology</i> , 2020, 43, 1209-1215.	1.9	9
89	Chronic kidney disease: a high-risk group that deserves intensive lipid lowering. <i>European Heart Journal</i> , 2020, 41, 4124-4126.	2.2	4
90	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 2020, 396, 1637-1643.	11.9	195

#	ARTICLE	IF	CITATIONS
91	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. JACC: CardioOncology, 2020, 2, 385-396.	5.2	10
92	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care, 2020, 43, 1843-1850.	9.0	28
93	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	0.5	113
94	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. American Journal of Medicine, 2020, 133, 1302-1312.	1.4	1
95	Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the <sc>Pinnacle</sc> registry. Clinical Cardiology, 2020, 43, 743-751.	1.9	15
96	The effect of canagliflozin on amputation risk in the <sc>CANVAS</sc> program and the <sc>CREDENCE</sc> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.	4.5	35
97	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology, 2020, 318, 126-129.	1.6	20
98	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	3.4	5
99	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs, 2020, 80, 995-1005.	10.8	10
100	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	6.3	9
101	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 128-135.	1.7	3
102	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 582.	6.3	82
103	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Journal of the American College of Cardiology, 2020, 75, 835-837.	5.5	1
104	Efficacy and safety of alirocumab in statin-intolerant patients over 3Âyears: open-label treatment period of the ODYSSEY ALTERNATIVE trial. Journal of Clinical Lipidology, 2020, 14, 88-97.e2.	1.5	14
105	Sodiumâ€Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e014908.	3.8	171
106	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.5	2
107	Outcomes of Renal Transplant Recipients after Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 125, 1305-1311.	1.5	2
108	Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2020, 75, 2119-2121.	5.5	27

#	ARTICLE	IF	CITATIONS
109	Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs. <i>Journal of the American Heart Association</i> , 2020, 9, e014975.	3.8	8
110	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	3.0	5
111	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008349.	4.1	19
112	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1057-1068.	5.5	32
113	Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019, 216, 30-41.	3.0	13
114	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	6.2	217
115	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. <i>Atherosclerosis</i> , 2019, 288, 85-93.	0.8	16
116	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846.	6.3	92
117	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	5.5	131
118	Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry. <i>ESC Heart Failure</i> , 2019, 6, 784-792.	3.0	48
119	Alteration of medical therapy in patients with heart failure relative to change in symptom severity. <i>ESC Heart Failure</i> , 2019, 6, 1085-1087.	3.0	2
120	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. <i>Journal of Clinical Lipidology</i> , 2019, 13, 979-988.e10.	1.5	13
121	Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2431-2433.	5.5	0
122	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019, 42, 1202-1209.	1.9	17
123	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	3.5	10
124	Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1580-1589.	3.5	42
125	Don't stop the statin!. <i>European Heart Journal</i> , 2019, 40, 3526-3528.	2.2	3
126	Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1562-1565.	3.5	1

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	11.9	551
128	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	6.3	207
129	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 618-620.	6.2	102
130	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019, 288, 194-202.	0.8	58
131	Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019, 213, 57-65.	3.0	7
132	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	5.5	74
133	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. <i>Journal of Clinical Lipidology</i> , 2019, 13, 443-454.	1.5	2
134	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	5.5	40
135	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	29.6	4,078
136	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	3.0	107
137	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	2.2	65
138	Ventricular depolarization limited to proximal septum: by which pathway?. <i>Europace</i> , 2019, 21, 681-681.	1.6	1
139	Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE). <i>European Heart Journal</i> , 2019, 40, 1837-1846.	2.2	78
140	Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2019, 123, 1202-1207.	1.5	13
141	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	3.0	13
142	Uniqueness of Coxeter structures on Kac—Moody algebras. <i>Advances in Mathematics</i> , 2019, 347, 1-104.	1.1	6
143	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post—PCI in Patients With—Atrial Fibrillation and Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2346-2355.	3.5	15
144	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	3.5	9

#	ARTICLE	IF	CITATIONS
145	Nitinol Stent Versus Bypass in Long Femoropopliteal Lesions. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2541-2549.	3.5	30
146	Outcomes of Women Compared With Men After Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022.	5.5	61
147	Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 339-345.	1.9	15
148	Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2019, 40, 218-219.	2.2	1
149	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	1.5	13
150	Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1121-1127.	4.5	41
151	Effect of Medication Co-payment Vouchers on P2Y ₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 44.	6.9	69
152	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	3.4	26
153	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019, 139, 1384-1395.	6.2	226
154	Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 3-11.	3.0	21
155	PCSK9 inhibitor valuation: A science-based review of the two recent models. <i>Clinical Cardiology</i> , 2018, 41, 544-550.	1.9	7
156	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	5.3	85
157	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. <i>Clinical Cardiology</i> , 2018, 41, 1022-1027.	1.9	6
158	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 473.	6.3	35
159	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	2.2	137
160	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 427-429.	3.4	1
161	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2018, 378, 484-486.	29.6	14
162	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 398-405.	4.3	28

#	ARTICLE	IF	CITATIONS
163	Simulation Models of Therapy Intensification in Lipid-Lowering Medicine—Reply. <i>JAMA Cardiology</i> , 2018, 3, 89.	6.3	1
164	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 292-302.	5.5	153
165	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT—TIMI 22. <i>Clinical Cardiology</i> , 2018, 41, 68-73.	1.9	5
166	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1571-1582.	6.2	325
167	A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 580-588.	3.5	59
168	Individualizing Blood Pressure Targets for People With Diabetes and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1319.	6.9	49
169	Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 830-838.	1.8	23
170	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , 2018, 131, 813-819.e5.	1.4	17
171	Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. <i>American Heart Journal</i> , 2018, 195, 50-59.	3.0	20
172	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of) Tj ETQq 0 0 rBT /Overlock 10 Tf 50 38 Metabolism, 2018, 20, 654-659.	4.5	31
173	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , 2018, 39, 2540-2545.	2.2	123
174	Should real-world evidence be incorporated into regulatory approvals?. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1155-1159.	2.4	13
175	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 1160.	6.3	59
176	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3370-3372.	5.5	104
177	Gender Equity Trends in Academic Productivity and Influence by Subspecialties of Cardiology. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3228-3229.	5.5	5
178	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	11.1	107
179	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009114.	3.8	19
180	Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, e009077.	3.8	38

#	ARTICLE	IF	CITATIONS
181	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. <i>Journal of the American Heart Association</i> , 2018, 7, e009221.	3.8	19
182	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	2.2	28
183	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23.	3.0	177
184	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	3.0	40
185	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , 2018, 270, 245-252.	1.6	54
186	Early and Chronic Dipeptidylâ€Peptidaseâ€IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.8	10
187	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018, 9, 1317-1334.	2.5	24
188	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. <i>Diabetes Care</i> , 2018, 41, 1510-1515.	9.0	31
189	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. <i>Current Cardiology Reports</i> , 2018, 20, 55.	2.8	7
190	Long-term Safety and Efficacy of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-Year Data from LOWER. <i>Atherosclerosis Supplements</i> , 2018, 32, 24.	1.4	0
191	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	6.2	216
192	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	1.5	2
193	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	5.5	180
194	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	9
195	Response by Bohula et al to Letters Regarding Article, â€Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1 0.78431 4 rgBT /Overlock	3.0	9
196	Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. <i>Diabetes</i> , 2018, 67, 1123-P.	0.9	0
197	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 190-198.	1.6	20
198	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 500-510.	1.0	17

#	ARTICLE	IF	CITATIONS
199	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. Diabetes, Obesity and Metabolism, 2017, 19, 664-671.	4.5	53
200	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	3.0	36
201	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. Journal of the American Heart Association, 2017, 6, .	3.8	8
202	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	3.4	26
203	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology, 2017, 69, 911-921.	5.5	162
204	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: <sc>A</sc> sub-analysis of <sc>ODYSSEY COMBO II</sc>. Diabetes, Obesity and Metabolism, 2017, 19, 989-996.	4.5	47
205	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 187, 78-87.	3.0	17
206	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5	3.0	17
207	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the <sc>EXAMINE</sc> trial. Diabetes, Obesity and Metabolism, 2017, 19, 962-969.	4.5	28
208	Growth Differentiation Factor 15 at 1-Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	3.8	27
209	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	3.4	9
210	STREAM characterisation correction " Authors' reply. Lancet, The, 2017, 389, 2102-2103.	11.9	0
211	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 145-153.	2.2	19
212	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis, 2017, 263, 112-118.	0.8	5
213	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. Journal of the American Society of Nephrology: JASN, 2017, 28, 3034-3043.	0.5	32
214	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology, 2017, 40, 390-398.	1.9	16
215	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2017, 2, 547.	6.3	156
216	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting. JAMA Cardiology, 2017, 2, 478.	6.3	23

#	ARTICLE	IF	CITATIONS
217	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	3.4	100
218	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq0 0 0 rgBT30 Overlock10 Tf 50 6	3.4	100
219	Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in) Tj ETQq1 1 0 3 8 4 3 1 4 rgBT /Over	3.4	100
220	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	5.5	197
221	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq1 1 0 3 8 4 3 1 4 rgBT /Over	3.4	100
222	Addition or Removal of Guideline Directed Medical Therapy in Ambulatory Patients with Heart Failure with Reduced Ejection Fraction Relative to Change in Symptom Severity. An Analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, S51.	1.6	0
223	Anticoagulant Use in Heart Failure Patients with Atrial Fibrillation: Insights From the NCDR PINNACLE-AF Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, S58.	1.6	0
224	Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	48
225	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	29.6	1,135
226	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1217-1227.	29.6	814
227	Soluble interleukin-13 \pm 1: a circulating regulator of glucose. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E663-E671.	3.7	4
228	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	9
229	Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. <i>Open Heart</i> , 2017, 4, e000557.	2.4	4
230	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <i>Clinical Cardiology</i> , 2017, 40, 932-939.	1.9	46
231	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). <i>American Journal of Cardiology</i> , 2017, 120, 931-939.	1.5	26
232	Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 959.	6.3	128
233	Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. <i>Coronary Artery Disease</i> , 2017, 28, 190-197.	0.7	19
234	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	5.5	98

#	ARTICLE	IF	CITATIONS
235	Patients with Heart Failure with Mid-Range Ejection Fraction Have a Distinct Clinical Profile: An Analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, S51.	1.6	0
236	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	49
237	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2017, 136, 1860-1862.	6.2	2
238	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	2.2	49
239	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 322-323.	5.5	14
240	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". <i>Circulation</i> , 2016, 133, e463.	6.2	0
241	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	5.5	69
242	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	102
243	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. <i>American Heart Journal</i> , 2016, 177, 33-41.	3.0	13
244	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016, 129, 1002-1005.	1.4	36
245	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	3.0	25
246	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>American Heart Journal</i> , 2016, 182, 89-96.	3.0	15
247	Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. <i>Hypertension</i> , 2016, 68, 1355-1364.	4.9	95
248	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016, 37, 3576-3584.	2.2	73
249	Design and Rationale of the DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	1.9	66
250	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	4.9	21
251	Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	75
252	Reductions in Atherogenic Lipids and Major Cardiovascular Events. <i>Circulation</i> , 2016, 134, 1931-1943.	6.2	114

#	ARTICLE	IF	CITATIONS
253	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	4.1	83
254	Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry—Get With The Guidelines. <i>American Heart Journal</i> , 2016, 175, 1-8.	3.0	6
255	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. <i>Diabetes Care</i> , 2016, 39, 1267-1273.	9.0	48
256	Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	35
257	Lipoprotein-Associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	45
258	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 67, 353-361.	5.5	177
259	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e002951.	4.9	8
260	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	3.0	12
261	Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement. <i>American Journal of Medicine</i> , 2016, 129, 372-378.	1.4	17
262	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27.	3.0	6
263	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 1574-1581.	6.2	69
264	Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease) <i>TJ ETQq0 0.6 rgBT /Overlock 10</i>	0.6	0
265	Should all surgery patients get statins pre-operatively? Clear or blurry VISION?. <i>European Heart Journal</i> , 2016, 37, 186-188.	2.2	2
266	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. <i>Journal of Clinical Lipidology</i> , 2015, 9, 758-769.	1.5	403
267	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	29.6	3,486
268	Point-of-Care Platelet Function Testing Predicts Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Bypass Grafting: Verify Pre-Op TIMI 45—A Pilot Study. <i>Clinical Cardiology</i> , 2015, 38, 92-98.	1.9	46
269	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , 2015, 169, 906-915.e13.	3.0	305
270	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. <i>Journal of the American College of Cardiology</i> , 2015, 65, 465-476.	5.5	30

#	ARTICLE	IF	CITATIONS
271	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Tj ETQq1 1 0.784314 rgBT /Overlo 2015, 9, 65-71.	1.5	24
272	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 1186-1194.	2.2	356
273	Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. <i>Europace</i> , 2015, 17, 855-863.	1.6	27
274	PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. <i>European Heart Journal</i> , 2015, 36, 2415-2424.	2.2	97
275	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet, The</i> , 2015, 385, 2264-2271.	11.9	586
276	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015, 385, 2067-2076.	11.9	666
277	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Hypertension</i> , 2015, 65, 1372-1407.	4.9	98
278	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002490.	3.8	39
279	Ezetimibe plus a Statin after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 1473-1477.	29.6	28
280	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233.	6.2	279
281	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. <i>American Journal of Medicine</i> , 2015, 128, 426.e1-426.e9.	1.4	32
282	Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial. <i>American Heart Journal</i> , 2015, 169, 132-141.e2.	3.0	9
283	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. <i>EuroIntervention</i> , 2015, 11, 737-745.	3.3	55
284	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014, 25, 517-525.	2.0	142
285	Operative Management of Metastatic Melanoma in Bone May Require En Bloc Resection of Disease. <i>Clinical Orthopaedics and Related Research</i> , 2014, 472, 3196-3203.	1.4	14
286	Quality of Care for Patients With Acute Coronary Syndromes as a Function of Hospital Revascularization Capability: Insights From Get With The Guidelinesâ€œ<sc>CAD</sc>. <i>Clinical Cardiology</i> , 2014, 37, 285-292.	1.9	17
287	Update on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification and Patient Selection. <i>American Journal of Medicine</i> , 2014, 127, e16-e17.	1.4	1
288	Clinical Implications and Correlates of Q Waves in Patients With <sc>ST</sc>â€œElevation Myocardial Infarction Treated With Fibrinolysis: Observations from the <sc>CLARITYâ€œTIMI</sc> 28 Trial. <i>Clinical Cardiology</i> , 2014, 37, 160-166.	1.9	4

#	ARTICLE	IF	CITATIONS
289	Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among <sc>US</sc> Cardiologists. <i>Clinical Cardiology</i> , 2014, 37, 103-107.	1.9	13
290	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	6.9	382
291	Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 543-549.	2.1	42
292	Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2014, 113, 76-83.	1.5	81
293	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	6.2	102
294	Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 63, 225-232.	5.5	31
295	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	29.6	481
296	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014, 168, 68-75.e2.	3.0	18
297	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	2.2	175
298	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 170, e59-e62.	1.6	10
299	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 520-527.	5.5	162
300	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. <i>American Journal of Medicine</i> , 2014, 127, 53-60.e1.	1.4	45
301	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014, 100, 1762-1769.	3.7	39
302	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. <i>European Heart Journal</i> , 2014, 35, 2864-2872.	2.2	241
303	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. <i>International Journal of Cardiology</i> , 2014, 176, 300-302.	1.6	4
304	BIOMARKERS FOR PREDICTION OF OUTCOMES IN REVASCULARIZED PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: A PLATO SUBSTUDY. <i>Journal of the American College of Cardiology</i> , 2014, 63, A45.	5.5	0
305	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1493-1499.	5.5	47
306	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1.	3.0	93

#	ARTICLE	IF	CITATIONS
307	Use of Renin-angiotensin System Blockers in Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 227-235.	3.4	10
308	Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 233-239.	2.2	11
309	Should We Measure Quality by the Dose?. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1802-1803.	5.5	0
310	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	29.6	2,280
311	Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. <i>Circulation</i> , 2013, 127, 673-680.	6.2	72
312	Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 35-40.	5.5	46
313	Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis. <i>American Journal of Medicine</i> , 2013, 126, 693-700.e1.	1.4	123
314	Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2013, 126, 74.e1-74.e9.	1.4	51
315	Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 555-559.	2.1	13
316	Ticagrelor in Patients With Acute Coronary Syndromes and Stroke. <i>Stroke</i> , 2013, 44, 1477-1479.	5.0	6
317	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. <i>Journal of Lipid Research</i> , 2013, 54, 467-472.	4.1	53
318	Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1711.	6.9	418
319	Very Large Database of Lipids: Rationale and Design. <i>Clinical Cardiology</i> , 2013, 36, 641-648.	1.9	39
320	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting. <i>Clinical Cardiology</i> , 2013, 36, 585-594.	1.9	16
321	Relationship of Race/Ethnicity With Door-to-balloon Time and Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction: Findings From Get With the Guidelines-Coronary Artery Disease. <i>Clinical Cardiology</i> , 2013, 36, 749-756.	1.9	48
322	Predictors of Long-term Adherence to Evidence-based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry. <i>Clinical Cardiology</i> , 2013, 36, 721-727.	1.9	72
323	Synthesizing Lessons Learned From Get With The Guidelines. <i>Circulation</i> , 2013, 128, 2447-2460.	6.2	112
324	Relation Between Time of Symptom Onset of ST-segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. <i>Clinical Cardiology</i> , 2013, 36, 222-227.	1.9	20

#	ARTICLE	IF	CITATIONS
325	Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2013, 36, 139-145.	1.9	24
326	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. <i>European Heart Journal</i> , 2013, 34, 1204-1214.	2.2	173
327	Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials" <i>Stroke</i> , 2013, 44, e95-6.	5.0	0
328	Care and Outcomes of Asian-American Acute Myocardial Infarction Patients: Findings From the American Heart Association Get With The Guidelines-Coronary Artery Disease Program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 126-133.	3.4	28
329	Guideline Adherence After ST-Segment Elevation Versus Non-ST Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 654-661.	3.4	43
330	Response to Letters Regarding Article, "Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial" <i>Circulation</i> , 2012, 125, .	6.2	1
331	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	2.2	2,494
332	Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO" <i>Circulation</i> , 2012, 126, .	6.2	1
333	Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. <i>Chronobiology International</i> , 2012, 29, 1390-1396.	1.9	14
334	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. <i>Circulation</i> , 2012, 125, 978-986.	6.2	180
335	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Circulation</i> , 2012, 126, 65-75.	6.2	703
336	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1623-1630.	5.5	81
337	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	5.5	2,601
338	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2012, 125, 1000-1009.	1.4	133
339	Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 680-688.	3.4	206
340	COX-2 Inhibitors and Cardiovascular Risk. <i>Science</i> , 2012, 336, 1386-1387.	19.6	117
341	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 203-210.	3.9	143
342	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 57, 672-684.	5.5	468

#	ARTICLE	IF	CITATIONS
343	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes [PLATO]) Trial. <i>Circulation</i> , 2011, 123, 1622-1632. Tj ETQq1 1 0.784314 rgt /Overdock 10 T	3.0	46
344	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trialâ€“Thrombolysis in Myocardial Infarction 22 (PROVE ITâ€“TIMI 22). <i>American Heart Journal</i> , 2011, 161, 1147-1155.e1.	3.0	80
345	Study design and rationale for the Stabilization of pLaques using Darapladibâ€“Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011, 162, 613-619.e1.	3.0	138
346	EXamination of Cardiovascular Outcomes with AlogliptIN versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). <i>American Heart Journal</i> , 2011, 162, 620-626.e1.	3.0	13
347	Statins and safety: can we finally be reassured?. <i>Lancet</i> , 2011, 378, 1980-1981.	11.9	202
348	In-Hospital Major Bleeding During ST-Elevation and Nonâ€“ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registryâ€“Get With The Guidelines. <i>American Journal of Cardiology</i> , 2011, 107, 1136-1143.	1.5	152
349	Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function) Tj ETQq1 1 0.784314 rgt /Overdock 10 T	3.0	18
350	Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registryâ€“Get With The Guidelines (GWTC)â€™ acute myocardial infarction mortality model and risk score. <i>American Heart Journal</i> , 2011, 161, 113-122.e2.	3.0	1,204
351	A Report of Quality Improvement in the Care of Patients With Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2011, 10, 29-34.	0.4	169
352	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1097.	6.9	248
353	Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 123, 1622-1632.	6.2	7
354	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATElet inhibition and patient Outcomes (PLATO) trial. <i>BMJ: British Medical Journal</i> , 2011, 342, d3527-d3527.	5.6	173
355	Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. <i>European Heart Journal</i> , 2011, 32, 1701-1703.	2.2	403
356	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. <i>European Heart Journal</i> , 2011, 32, 2945-2953.	2.2	6
357	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2011, 124, 544-554.	6.2	40
358	Clopidogrel: To Test or Not to Test? That Is the Questionâ€“Still. <i>Clinical Chemistry</i> , 2011, 57, 659-661.	3.4	40
359	Comparison of Composite Measure Methodologies for Rewarding Quality of Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 610-618.	3.4	40
360	Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH]) Tj ETQq0 0 0 rgt /Overdock 10 T	0.0	40

#	ARTICLE	IF	CITATIONS
361	What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?. <i>Circulation</i> , 2010, 122, 2142-2151.	6.2	208
362	Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE®). <i>Critical Pathways in Cardiology</i> , 2010, 9, 55-81.	0.4	8
363	Physician Practice Patterns in Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2010, 9, 23-29.	0.4	4
364	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2010, 363, 2406-2415.	29.6	708
365	The Midterm Elections "High Stakes for Health Policy. <i>New England Journal of Medicine</i> , 2010, 363, 1685-1687.	29.6	12
366	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1456-1462.	5.5	346
367	Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2010, 122, 2131-2141.	6.2	479
368	An update on the IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. <i>American Heart Journal</i> , 2010, 159, 705-709.	3.0	82
369	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T patients with coronary heart disease. <i>American Heart Journal</i> , 2010, 160, 655-661.e2.	3.0	113
370	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2010, 160, 1130-1136.e3.	3.0	33
371	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. <i>Lancet, The</i> , 2010, 375, 283-293.	11.9	624
372	Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. <i>Lancet, The</i> , 2010, 375, 1536-1544.	11.9	551
373	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. <i>Circulation</i> , 2010, 122, 1056-1067.	6.2	357
374	Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 424-430.	3.9	136
375	Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 633-641.	3.4	73
376	A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 491-499.	3.4	188
377	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. <i>Clinical Chemistry</i> , 2009, 55, 265-273.	3.4	55
378	Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. <i>European Heart Journal</i> , 2009, 30, 1195-1202.	2.2	167

#	ARTICLE	IF	CITATIONS
379	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. <i>Circulation</i> , 2009, 120, 560-567.	6.2	69
380	Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2207.	6.9	84
381	Get With the Guidelines—Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2009, 119, 107-115.	6.2	510
382	Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance. <i>American Journal of Cardiology</i> , 2009, 103, 1051-1055.	1.5	64
383	Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 104, 1171-1178.	1.5	26
384	Design of the DEFINE trial: Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib. <i>American Heart Journal</i> , 2009, 158, 513-519.e3.	3.0	87
385	The Relative Efficacy and Safety of Clopidogrel in Women and Men. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1935-1945.	5.5	125
386	Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2358-2362.	5.5	160
387	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	29.6	6,143
388	Acute Coronary Syndromes: Diagnosis and Management, Part I. <i>Mayo Clinic Proceedings</i> , 2009, 84, 917-938.	2.8	314
389	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009, 157, 599-605.	3.0	369
390	Can the polypill save the world from heart disease?. <i>Lancet, The</i> , 2009, 373, 1313-1314.	11.9	31
391	Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States. <i>Critical Pathways in Cardiology</i> , 2009, 8, 91-97.	0.4	17
392	Individual Quality Improvement in Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2009, 8, 43-48.	0.4	7
393	Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. <i>Critical Pathways in Cardiology</i> , 2009, 8, 29-33.	0.4	17
394	Special Considerations in Acute Coronary Syndromes. , 2009, , 123-140.		0
395	Post-Hospitalization Care of Patients with Acute Coronary Syndrome. , 2009, , 173-208.		0
396	ST-Segment-Elevation Myocardial Infarction. , 2009, , 79-121.		0

#	ARTICLE	IF	CITATIONS
397	Complications of Acute Coronary Syndrome. , 2009, , 141-172.		1
398	Pathophysiology of Acute Coronary Syndromes. , 2009, , 1-12.		0
399	Unstable Angina and Non-ST-Elevation Myocardial Infarction. , 2009, , 37-78.		0
400	Use of Aldosterone Antagonists in Heart Failure. JAMA - Journal of the American Medical Association, 2009, 302, 1658.	6.9	233
401	Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database). American Journal of Cardiology, 2008, 101, 1242-1246.	1.5	11
402	Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
403	Mixed Dyslipidemia, Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease: Clinical Implications. American Journal of Cardiology, 2008, 102, 5L-9L.	1.5	79
404	Obesity-Related Cardiometabolic Complications. Clinical Cornerstone, 2008, 9, 11-22.	1.0	20
405	Cardiovascular Disease and Modifiable Cardiometabolic Risk Factors. Clinical Cornerstone, 2008, 9, 24-41.	1.0	20
406	Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology, 2008, 51, 724-730.	5.5	548
407	Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. Journal of the American College of Cardiology, 2008, 52, 914-920.	5.5	64
408	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal, 2008, 155, 910-917.	3.0	39
409	Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: Insights from American Heart Association's Get With the Guidelines program. American Heart Journal, 2008, 155, 1059-1067.	3.0	77
410	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 0 rgBT /Overlock 10 T outcomes in patients with acute coronary syndromes. American Heart Journal, 2008, 156, 826-832.	3.0	283
411	Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. European Heart Journal, 2008, 29, 1096-1102.	2.2	168
412	Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction. Circulation, 2008, 117, 1936-1944.	6.2	296
413	Acute ST-Segment Elevation Myocardial Infarction. Chest, 2008, 133, 708S-775S.	0.8	110
414	Antithrombotic Therapy for Non-â€œST-Segment Elevation Acute Coronary Syndromes. Chest, 2008, 133, 670S-707S.	0.8	145

#	ARTICLE	IF	CITATIONS
415	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-Segment Elevation Myocardial Infarction Critical Pathway Toolkit. <i>Critical Pathways in Cardiology</i> , 2008, 7, 223-231.	0.4	4
416	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) Unstable Angina/Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit. <i>Critical Pathways in Cardiology</i> , 2008, 7, 43-81.	0.4	7
417	An Organized Approach to Improvement in Guideline Adherence for Acute Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2008, 168, 1813.	3.7	113
418	ADP Receptor Antagonists. , 2008, , 87-123.		3
419	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 552-574.	3.4	387
420	Diabetes and Mortality Following Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 765.	6.9	578
421	Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 1800-1807.	3.4	72
422	Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. <i>Circulation</i> , 2007, 115, 2761-2788.	6.2	699
423	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. <i>Circulation</i> , 2007, 115, e356-75.	6.2	350
424	Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1844-1851.	5.5	475
425	Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1852-1856.	5.5	443
426	Introduction: Rationale for Tight Control of Hyperglycemia. <i>American Journal of Cardiology</i> , 2007, 99, S1-S4.	1.5	2
427	High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. <i>Clinical Cornerstone</i> , 2007, 8, S14-S23.	1.0	19
428	Cardiovascular disease and modifiable cardiometabolic risk factors. <i>Clinical Cornerstone</i> , 2007, 8, 11-28.	1.0	128
429	Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. <i>Lancet</i> , The, 2006, 368, 1771-1781.	11.9	461
430	The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 48, 37-42.	5.5	60
431	Acute Clopidogrel Use and Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2006, 48, 281-286.	5.5	179
432	Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2006, 48, 438-445.	5.5	677

#	ARTICLE	IF	CITATIONS
433	Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. <i>American Heart Journal</i> , 2006, 152, 237-245.	3.0	62
434	The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. <i>Current Opinion in Lipidology</i> , 2006, 17, 626-630.	2.8	24
435	Early Invasive Strategy Improves Outcomes in Patients With Acute Coronary Syndrome With Previous Coronary Artery Bypass Graft Surgery. <i>Critical Pathways in Cardiology</i> , 2006, 5, 167-172.	0.4	26
436	Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2006, 98, 681-684.	1.5	131
437	Critical Pathways Using Platelet Testing to Potentially Optimize the Use of Oral Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2006, 98, S33-S38.	1.5	7
438	Evolving Management of ST-Segment Elevation Myocardial Infarction: Update on Recent Data. <i>American Journal of Cardiology</i> , 2006, 98, S10-S21.	1.5	13
439	Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2006, 114, 2019-2025.	6.2	472
440	Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2006, 114, 550-557.	6.2	169
441	Lipoprotein-Associated Phospholipase A ₂ and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Circulation</i> , 2006, 113, 1745-1752.	6.2	212
442	Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. <i>European Heart Journal</i> , 2006, 27, 2323-2329.	2.2	89
443	The endocannabinoid system:A new approach to control cardiovascular disease. <i>Clinical Cornerstone</i> , 2005, 7, 17-26.	1.0	7
444	Acute Coronary Syndromes: Risk Stratification and Initial Management. <i>Cardiology Clinics</i> , 2005, 23, 401-409.	2.1	14
445	Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2005, 80, 768-779.	1.4	60
446	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. <i>American Heart Journal</i> , 2005, 149, 227-233.	3.0	51
447	C-Reactive Protein Levels and Outcomes after Statin Therapy. <i>New England Journal of Medicine</i> , 2005, 352, 20-28.	29.6	2,131
448	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1411-1416.	5.5	313
449	The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1425-1433.	5.5	249
450	Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. <i>New England Journal of Medicine</i> , 2005, 352, 1179-1189.	29.6	1,743

#	ARTICLE	IF	CITATIONS
451	Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2096.	6.9	529
452	Utilization of Guidelines and Computer-Based Technology to Achieve Optimal Care in Atherothrombotic Vascular Disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 45-49.	2.2	2
453	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 350, 1495-1504.	29.6	4,578
454	Age and Routine Invasive Management of Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2004, 141, 967.	10.0	0
455	Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part I. <i>Clinical Cardiology</i> , 2003, 26, 358-364.	1.9	11
456	The next step in cardiovascular protection. <i>Atherosclerosis Supplements</i> , 2003, 4, 3-9.	1.4	6
457	Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. <i>American Heart Journal</i> , 2003, 145, 622-627.	3.0	133
458	Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003, 24, 1815-1823.	2.2	806
459	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. <i>Archives of Internal Medicine</i> , 2003, 163, 2345.	3.7	1,904
460	Treatment Algorithms and Critical Pathways for Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 425-432.	1.9	6
461	PROVE-IT TIMI 22 Study. <i>Critical Pathways in Cardiology</i> , 2003, 2, 188-196.	0.4	6
462	Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 1760-1763.	6.2	683
463	Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1851.	6.9	123
464	Palm Pilot Programs to Improve Quality of Care in Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2002, 1, 113-115.	0.4	1
465	Critical pathways for management of patients with acute coronary syndromes: An assessment by the National Heart Attack Alert Program. <i>American Heart Journal</i> , 2002, 143, 777-789.	3.0	54
466	Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) TIMI 22 trial. <i>American Journal of Cardiology</i> , 2002, 89, 860-861.	1.5	118
467	The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2001, 345, 1014-1021.	29.6	1,220
468	Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. <i>New England Journal of Medicine</i> , 2001, 344, 1879-1887.	29.6	1,927

#	ARTICLE	IF	CITATIONS
469	"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 207-216.	2.2	1
470	Importance of TIMI 3 Flow. <i>Circulation</i> , 2001, 104, 624-626.	6.2	60
471	Ischemic Preconditioning: Implications for the Geriatric Heart. <i>The American Journal of Geriatric Cardiology</i> , 2001, 10, 145-151.	0.7	4
472	Review: Glycoprotein IIb/IIIa inhibitors reduce combined end points in acute coronary syndromes. <i>ACP Journal Club</i> , 2001, 134, 49.	0.1	0
473	Reducing Medication Errors Potential Benefits of Bolus Thrombolytic Agents. <i>Academic Emergency Medicine</i> , 2000, 7, 1285-1289.	1.8	14
474	Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 235-241.	2.2	9
475	Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials. <i>Clinical Cardiology</i> , 2000, 23, 14-17.	1.9	18
476	Relationship of Symptom-Onset-to-Balloon Time and Door-to-Balloon Time With Mortality in Patients Undergoing Angioplasty for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2941.	6.9	1,056
477	Advances in the medical management of acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 7, 171-189.	2.2	7
478	The role of cardiac Troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. <i>Clinical Cardiology</i> , 1999, 22, 13-16.	1.9	21
479	Breaking the therapeutic barriers: New Strategies for acute coronary syndromes. <i>Clinical Cardiology</i> , 1999, 22, 1-2.	1.9	40
480	Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: Unstable angina/non-ST-segment elevation myocardial infarction. <i>Clinical Cardiology</i> , 1999, 22, 30-36.	1.9	27
481	Combination therapy for acute myocardial infarction: Glycoprotein IIb/IIIa inhibitors plus thrombolysis. <i>Clinical Cardiology</i> , 1999, 22, 37-43.	1.9	21
482	Low molecular weight heparin in acute coronary syndromes. <i>Current Cardiology Reports</i> , 1999, 1, 206-211.	2.8	0
483	Prehospital thrombolysis: An idea whose time has come. <i>Clinical Cardiology</i> , 1999, 22, 10-19.	1.9	27
484	The Open Artery Hypothesis: Past, Present, and Future. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 101-112.	2.2	3
485	Protection Conferred by Preinfarct Angina is Manifest in the Aged Heart: Evidence from the TIMI 4 Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 6, 89-92.	2.2	48
486	C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1460-1465.	5.5	724

#	ARTICLE	IF	CITATIONS
487	Circadian Variation in the Onset of Unstable Angina and Non-Q-Wave Acute Myocardial Infarction (The Tj ETQq1	1.0,784314	116
488	Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. Journal of Thrombosis and Thrombolysis, 1996, 3, 117-125.	2.2	33
489	Time to treatment: A crucial factor in thrombolysis and primary angioplasty. Journal of Thrombosis and Thrombolysis, 1996, 3, 249-255.	2.2	15
490	Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 1996, 335, 1342-1349.	29.6	1,600
491	Diagnosis of Acute Coronary Syndrome. , 0, , 13-35.		1
492	Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from the GUSTO-III trial. Understanding of low-density lipoprotein cholesterol and dyslipidemia management () Tj ETQq0 0 19 BT / Overlock 10		1